Efficacy and adverse events of octreotide long-acting release in acromegaly: a real-world retrospective study.

ABSTRACT:

Background

Octreotide long-acting release (LAR) is a common drug used for acromegaly that aims to normalize serum growth hormone (GH) and insulin-like growth factor-1 (IGF-1). However, only a few studies have evaluated its efficacy and safety in Chinese patients. This retrospective study aimed to assess its efficacy and safety in a cohort of Chinese patients with acromegaly.

Methods

A total of 163 patients with acromegaly, who received continuous and regular octreotide LAR treatment at least three times at Peking Union Medical College Hospital between 2010 and 2020, were enrolled. Clinical characteristics, acromegaly activity, and other laboratory tests before and after treatment were collected for analysis.

Results

The study enrolled 163 patients, including 71 men (4

SUBMITTER: Zhao Z 

PROVIDER: S-EPMC9358514 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature